Aqueous Extract of Bambusae Caulis in Taeniam Inhibits PMA-Induced Tumor Cell Invasion and Pulmonary Metastasis: Suppression of NF-κB Activation through ROS Signaling

Aeyung Kim*, Minju Im*, Nam-Hui Yim, Young Pil Jung, Jin Yeul Ma*
Korean Medicine (KM)-Based Herbal Drug Development Group, Korea Institute of Oriental Medicine (KIOM), Daejeon, Republic of Korea

Abstract

Bamboo shavings (Bambusae Caulis in Taeniam, BCT) are widely used as a traditional Chinese medicine to control hypertension and cardiovascular disease, and to alleviate fever, vomiting, and diarrhea. It has been demonstrated that BCT reduces ovalbumin-induced airway inflammation by regulating pro-inflammatory cytokines, and decreases tumor growth in tumor-bearing mice. However, the effects of BCT on the metastatic potential of malignant cancer cells and the detailed mechanism of its anti-metastatic activity have not been examined previously. In this study, we investigated whether an aqueous extract of BCT (AE-BCT) reduces the metastatic potential of HT1080 cells, and elucidated the underlying anti-metastatic mechanism. In addition, we examined whether AE-BCT administration inhibits pulmonary metastasis of intravenously injected B16F10 cells in C57BL/6J mice. AE-BCT (50–250 μg/ml) dose-dependently suppressed colony-forming activity under anchoragedependent and -independent growth conditions. Pretreatment with AE-BCT efficiently inhibited cell migration, invasion, and adhesion. AE-BCT also dramatically suppressed PMA-induced MMP-9 activity and expression by blocking NF-κB activation and ERK phosphorylation. Production of intracellular ROS, a key regulator of NF-κB activation, was almost completely blocked by pretreatment with AE-BCT. Furthermore, daily oral administration of AE-BCT at doses of 50 and 100 mg/kg efficiently inhibited lung metastasis of B16F10 cells injected into the tail veins of C57BL/6J mice with no systemic toxicity. These results demonstrate that AE-BCT significantly reduced the metastatic activity of highly malignant cancer cells by suppressing MMP-9 activity via inhibition of ROS-mediated NF-κB activation. These results indicate that AE-BCT may be a safe natural product for treatment of metastatic cancer.

Introduction

Cancer metastasis, the spread of cancer cells from the primary neoplasm to distant organs via blood or lymph vessels and their subsequent outgrowth, is a major cause of death in cancer patients and remains a challenge in cancer treatment [1,2]. Metastasis is a multi-step process involving cell mobilization, cell invasion due to degradation of the extracellular matrix (ECM), adhesion to endothelial cells, extravasation leading to infiltration into the underlying tissue, and formation of metastatic foci [3]. Degradation of the ECM and components of basement membranes plays an essential role in metastasis and is caused by the action of proteinases, such as matrix metalloproteinases (MMPs), serine proteinases, cathepsins, and plasminogen activators (PAs) [4–6]. Among these proteinases, MMP-9 is abundantly expressed in various malignant tumors and is considered to be closely associated with tumor progression, metastasis, and angiogenesis [7–9]. Thus, the search for agents capable of reducing MMP-9 activity by targeting upstream regulatory pathways is important for controlling cancer metastasis.

Several studies reported that reactive oxygen species (ROS) participate in the activation of NF-κB, a key player in tumorigenesis, and that excess ROS produced by cancer cells trigger tumor invasion and angiogenesis via NF-κB-mediated MMP-9 activation [10,11]. ROS scavenging and/or inhibition of NF-κB activation lead to the suppression of MMP-9 activity and further tumor invasion [12].

Bamboo shavings (Bambusae Caulis in Taeniam, BCT), the green middle layer of the stems of Phyllostachys nigra var. henosis or Phyllostachys bambusoides, can be obtained by scraping off the bark from bamboo stems, cutting the stems into slices, binding them together, and drying them in shaded places. BCT has been used as a traditional Chinese medicine for the treatment of hypertension and cardiovascular disease in China and Korea. Additionally, BCT has been recorded to relieve fever, vomiting, stomachache, diarrhea, and chest diaphragm inflammation in the material media of past dynasties in Chinese history, and has been...
certificated as a functional food material by the Ministry of Health in China [13,14]. Recent studies reported that the ethyl acetate fraction of BCT (BCE) reduces ovalbumin-induced airway inflammation, and inhibits the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 in LPS-stimulated RAW264.7 cells by inducing NF-E2-related factor 2 (Nrf2)-mediated HO-1 via p38 MAPK signaling [15,16]. BCE exerted neuroprotective effects against glutamate-induced cytotoxicity in HT22 cells through the HO-1 and Nrf2 signaling pathways [17]. The MeOH extract of BCT was demonstrated to reduce total cholesterol and low-density lipoprotein (LDL)-cholesterol levels in rats with hyperlipidemia induced by Triton WR-130 and a high-cholesterol diet, suggesting that BCT is a good candidate for the treatment of blood circulatory disorders, obesity, and hyperlipidemia [18]. Lu et al. reported that a triterpenoid-rich extract of bamboo shavings (EBS) and its main component, friedelin, inhibited the growth of P388 and A549 tumor cells in vitro, and decreased tumor weights in a sarcoma-loaded mouse 180 model, indicating that EBS may have anti-tumor effects [19].

In this study, we evaluated the effect of AE-BCT on the metastatic potential of HT1080 malignant human fibrosarcoma cells in an in vitro system and investigated the detailed mechanism of AE-BCT’s anti-metastatic activity. Furthermore, we examined whether AE-BCT inhibited the pulmonary metastasis of B16F10 melanomas after intravenous injection without causing any adverse effects.

Materials and Methods
Cells and Mice
B16F10 murine melanoma cells, which are highly metastatic to the lungs of C57BL/6j mice, and HT1080 human fibrosarcoma cells were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Lonza, Walkersville, MD, USA) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (FBS; Gibco/Invitrogen, Carlsbad, CA, USA) and 100 U/mL penicillin/100 µg/mL streptomycin (Gibco/Invitrogen) at 37°C in a humidified 5% CO2 incubator. For experimental pulmonary metastasis, specific pathogen-free female C57BL/6j mice were purchased from Taconic Farms Inc. (Samtako Bio Korea, O-San, Korea) and maintained in our animal facility for 1 week before use. Mice were housed in a barrier facility with 12-h light-dark cycles under specific pathogen-free conditions at a temperature of 24±1°C and humidity of 55±5%. Animal experimental procedures were approved by Korea Institute of Oriental Medicine Care and Use Committee with a reference number of #13-011 and #13-042, and performed in accordance with the Korea Institute of Oriental Medicine Care Committee Guidelines.

Antibodies and Chemicals
A cytotoxicity detection kit (LDH, lactate dehydrogenase) and 3-(4,5-Dimethyl-2-thiazoly)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Roche Diagnostics (Mannheim, Germany) and Sigma Chemical Co. (St. Louis, MO, USA), respectively. Anti-IkBα, anti-phospho-IkBα (Ser32/36), anti-NF-κB p65, anti-MMP-9, and anti-tubulin antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-TATA sequence-binding protein (TBP) was obtained from Lifespan BioScience, Inc. (Seattle, WA, USA). Antibodies against p38, phospho-p38 (Thr180/Tyr182), extracellular signal-related kinase 1/2 (ERK), phospho-ERK (Thr202/Tyr204), c-jun-N-terminal kinase (JNK), phospho-JNK (Thr183/Tyr185), and HRP-conjugated secondary antibodies were obtained from Cell Signaling Technology.

Preparation for Aqueous Extract of BCT (AE-BCT)
Commercial dried BCT was purchased from Yeongcheon Oriental Herbal Market (Yeongcheon, Korea), confirmed by Professor Ki Hwan Baek of the College of Pharmacy, Chungnam National University (Daejeon, Korea), and deposited in the herbal bank in the Korea Institute of Oriental Medicine (KIOM, Daejeon, Korea). To prepare AE-BCT, the dried parts of the Bambuseae Caulis in Taenium (50.0 g) were placed in 1 L of distilled water and heat-extracted for 3 h at 115°C in an extractor (Cosmos-600 Extractor, Gyconseo Co., Inchon, Korea). AE-BCT was filtered using standard testing sieves (150 µm, Retsch, Haan, Germany), and then concentrated to dryness in a lyophilizer. Freeze-dried AE-BCT powder (50 mg) was dissolved in 1 mL distilled water, filtered through a 0.22 µm disk filter, and stored at −20°C until use.

Cytotoxicity Assay
To evaluate cytotoxicity, MTT and LDH release assays were used. Briefly, cells (5×104 cells/well/96-well plate) were incubated with AE-BCT at the concentrations between 10 and 250 µg/mL. After 48 h treatment, cells were incubated with 10 µL MTT solution (5 mg/mL in PBS) for additional 4 h. After dissolving formazan precipitates with dimethyl sulfoxide (DMSO), the absorbance at 570 nm was measured with Infinite M200 microplate reader (TECAN Group Ltd. Switzerland). LDH release into the culture supernatant from AE-BCT-treated cells was determined by a commercial cytotoxicity detection kit according to the manufacturer’s instructions.

Colony Formation Assay
Two hundred cells seeded in a 12-well culture plate in 1 mL 10% FBS/DMEM were incubated to allow attachment. After adding AE-BCT at the indicated concentrations, cells were incubated for 7~10 days and colonies were stained with 0.2% crystal violet/20% methanol (wt/vol) solution.

Anchorage-independent Colony Formation Assay
To determine anchorage-independent cell growth, cells (5×104) suspended in 2 mL medium containing specified concentration of AE-BCT, 0.3% agar and 10% FBS were applied to the solidified bottom agar containing 0.6% agar and 10% FBS. During 2 weeks of incubation, colonies on soft agar were observed under a phase-contrast microscope and photographed.

Wound-healing Assay
After preincubation with 25 µg/mL mitomycin C (Sigma Chemical Co.) for 30 min, injury lines were drawn on a confluent monolayer of cells. After eliminating detached cell debris, cells were allowed to migrate in the presence of AE-BCT and migration was observed under a phase-contrast microscope at the specific time points.

In Vitro Migration and Invasion Assays
Using a Transwell chamber with a 10 mm diameter and 8 µm pore size polycarbonate membrane (Corning Costar, Cambridge, MA), the migration and invasion assays were performed. Cells were pre-treated with or without indicated concentrations of AE-BCT for 12 h and harvested. After filling the lower chamber with 600 µL 10% FBS/DMEM, cells (1×105) suspended in 100 µL serum-free DMEM were added to each upper chamber and...
Figure 1. Effect of AE-BCT on the viability and colony-forming activity of HT1080 cells. Cells seeded onto a 96-well culture plate were treated with 25 to 5000 μg/mL AE-BCT with or without serum for 48 h. Cell cytotoxicity was estimated by MTT (A) and LDH release (B) assays. (C) Representative photographs of anchorage-dependent colony formation in the presence or absence of AE-BCT. At the end of incubation, cells were
incubated at 37°C. Cells remained to the upper surface of the filters were removed and then filters were stained with 0.2% crystal violet/20% methanol (wt/vol) solution. The invasion assay was conducted after coating the Transwell chamber with 20 μL 1:2 mixture of Matrigel:DMEM (Matrigel; BD Biosciences, Bedford, MA, USA) as the intervening invasive barrier. Migration and invasion were monitored after 12 h and 24 h incubation, respectively.

**Cell-adhesion Assay on Immobilized FN and Collagen**

A cell-to-ECM adhesion assay was performed in 96-well culture plates using a method reported previously [20], with slight modifications. The wells were coated overnight at room temperature with 50 μL of 5 μg/mL FN (Sigma) or 50 μL of 0.3% type I collagen solution (Cellmatrix type I-A; Nittazcerachin Co., Osaka, Japan), washed twice with cold PBS, blocked with 0.2 mL of DMEM containing 3% BSA for 1 h at 37°C, and then washed. Cells pre-treated with or without indicated concentrations of AE-BCT for 12 h were suspended in serum-free DMEM (1×10^5/200 μL), plated on ECM-coated culture plates, and then incubated for 1 h at 37°C in a 5% CO2 incubator. Cells were washed twice to remove unattached cells. Cells attached to the matrix were then stained with a 0.2% crystal violet/20% methanol (wt/vol) solution at room temperature for 30 min. Once stained, the cells were dissolved in 0.2 mL of a 1% sodium dodecyl sulfate (SDS) solution and the spectrophotometric absorbance at 560 nm was measured.

**MMP-9 Activity Assay**

Cells were pre-incubated with AE-BCT at the specified concentrations in serum-free DMEM for 12 h and then stimulated with 5 nM 12-phorbol-13-myristate acetate (PMA) or 20 ng/mL tumor necrosis factor-α (TNF-α) for an additional 24 h. Serum-free conditioned medium was collected and centrifuged to remove cell debris. In the case of the B16F10 cells, each conditioned medium was concentrated using a Centricon (Amicon Ultra Centrifugal filter, 10K, Millipore Co., Billerica, MA). After the equivalent volumes of the conditioned medium were electrophoresed, electrotransferred to a nitrocellulose membrane, then immunoblotted. Proteins were visualized using a PowerOpti-ECL Western blotting detection reagent (Animal Genetics, Inc. Korea) and an ImageQuant LAS 4000 mini (GE Healthcare, Piscataway, NJ, USA), and band intensities were calculated using ImageJ software (National Institutes of Health, USA).

**Measurement of Intracellular ROS Generation**

The intracellular ROS level was assessed by using the peroxide-sensitive fluorescent probe 2′,7′-dichlorofluorescein diacetate (DCF-DA, Sigma). Cells were stimulated with 5 nM PMA for 3 h with or without pre-incubation with AE-BCT (50 μg/mL) for 12 h or N-acetyl-L-cysteine (NAC, 1 mM) for 1 h, and were then incubated with DCF-DA (5 μM) for 30 min at 37°C. After washing the cells with PBS, intracellular ROS levels were immediately measured with a FACS Calibur flow cytometer using the CellQuest software (BD Biosciences, San Jose, CA) and analyzed using the WinMDI 2.8 software [J. Trotter, Scripps Research Institute, La Jolla, CA].

**In vivo Experimental Lung Metastasis Assay**

B16F10 cells (3×10^5 cells/0.2 mL PBS) were injected via the tail veins of the female C57BL/6J mice (day 0). The mice were randomly divided into three groups (n=5 for each group) and administration of AE-BCT started simultaneously with the induction of metastasis. AE-BCT at the doses of 50 or 100 mg/kg/day and vehicle (saline) was orally administered to mice during 17 days. The mice were sacrificed, their lungs were fixed in Bouin’s solution (Sigma), and the number of B16F10 colonies present on the surface of each set of lungs was determined by a visual inspection.

**Safety Assessment of AE-BCT**

To assess the safety of AE-BCT, 6-week-old female C57BL/6J mice were daily administered 50 or 100 mg/kg AE-BCT (n=5). The mice were carefully observed for behavioral responses and their body weights were measured daily. At day 15, mice were sacrificed, organs (heart, lung, liver, spleen, and kidneys) were weighed, and blood samples were collected. Whole blood and serum were examined for hematological and serological parameters using ADVIA 2120i hematology system (Siemens Healthcare Diagnostics, Tarrytown, NY) and XL 200 (Erba Diagnostics Mannheim, Germany), respectively.

**Statistical Analysis**

Data are presented as the mean ± standard deviation (SD). Statistical significance of the difference between groups was analyzed using Student’s t-test with the Sigma Plot 8.0 software, and a p-value less than 0.05 was considered significant.

**Results**

**AE-BCT Suppresses the Anchorage-dependent and -independent Growth of HT1080 Cells at Non-toxic Concentrations**

We initially determined non-cytotoxic concentrations of AE-BCT in HT1080 cells by MTT and LDH assays. As shown in Fig. 1A and 1B, compared to untreated control cells, cell viability and LDH release were not significantly changed in cells treated with AE-BCT at concentrations ranging from 25 to 250 μg/mL. Thus, we used this AE-BCT concentration range in all subsequent experiments. Next, we investigated whether AE-BCT, at non-cytotoxic concentrations, can suppress anchorage-dependent or -independent cell growth.
Figure 2. Effect of AE-BCT on the in vitro migration, invasion, and adhesion to ECM of HT1080 cells. (A) Confluent cell monolayers were treated with mitomycin C (25 μg/mL) for 1 h and an injury line was drawn. Cell debris was removed by washing and the cells were incubated in medium containing 10% FBS with or without 50, 100, or 250 μg/mL AE-BCT. Wound migration was monitored using a phase-contrast microscope.
concentrations, could influence anchorage-dependent colony formation by HT1080 cells after seeding at a low density. Untreated control HT1080 cells showed rapid proliferation and formed sizable colonies from a single cell. AE-BCT treatment during incubation suppressed colony-forming activity in a dose-dependent manner, reducing the number of sizable colonies and colony sizes (Fig. 1C). AE-BCT, at concentrations of 50–250 µg/mL significantly suppressed anchorage-independent growth (the ability of cells to form colonies in semi-solid medium) by approximately 40–97% compared to untreated control cells (Fig. 1D).

AE-BCT Reduces Metastatic Potential

To examine the anti-metastatic effect of AE-BCT in vitro, we carried out wound healing assays to monitor cell motility. As shown in Fig. 2A, untreated control HT1080 cells migrated across the wound area, leading to approximately 50% healing at 36 h. AE-BCT treatment remarkably suppressed wound migration in a dose-dependent manner by approximately 60–90% compared to control cells. In a Transwell migration and invasion assay, serum-induced migratory activity was reduced significantly in AE-BCT-treated cells compared to control cells. In addition, invasiveness, the ability to invade a Matrigel barrier, was also considerably decreased in AE-BCT-treated cells. Treatment with 50–250 µg/mL AE-BCT dose-dependently inhibited migration and invasion by approximately 30–50% compared to untreated control cells (Fig. 2B). Since cell-to-ECM adhesion is believed to be a fundamental step in tumor invasion [21], we next examined the effect of AE-BCT on the adhesion of HT1080 cells to fibronectin (FN) and type I collagen. Pretreatment of HT1080 cells with AE-BCT reduced cell attachment to FN and collagen in a dose-

Figure 3. Effects of AE-BCT on MMP-9 activity and expression in HT1080 cells. Cells pre-treated with AE-BCT for 12 h were incubated in serum-free medium with or without 5 nM PMA for a further 24 h. Conditioned media were collected and analyzed for the activity and expression of MMP-9 by gelatin zymography (A) and Western blotting (B), respectively. Bar graphs shows fold increases in band intensity compared with untreated control cells. Data are expressed as means ± SD of three independent experiments. **p<0.01 vs untreated control, #p<0.01 vs PMA stimulation.

doi:10.1371/journal.pone.0078061.g003
dependent manner (Fig. 2C). However, pretreatment of ECM-coated wells with AE-BCT did not affect the adhesion capability of cells (data not shown). These anti-metastatic effects of AE-BCT were not due to the cytotoxicity, as shown in Fig. 1A and 1B.

**AE-BCT Suppresses PMA-induced MMP-9 Activity and Expression**

Because MMP-9 is known to play essential roles in cancer metastasis by degrading the surrounding ECM [8,9], we next examined whether AE-BCT can modulate the MMP-9 activity and expression by gelatin zymography and Western blotting, respectively. PMA was used as a potent inducer of MMP-9 activity and expression [22]. As shown in Fig. 3A and 3B, treatment with 50–250 µg/mL AE-BCT dramatically reduced the increases in MMP-9 activity and expression in response to PMA in a dose-dependent manner. The inhibitory effect in the resting state was negligible. In addition, increased secretion of active MMP-2 in response to PMA stimulation was confirmed by gelatin zymography and Western blotting; however, AE-BCT did not prevent PMA-induced MMP-2 activation (data not shown).

**AE-BCT Blocks PMA-induced NF-κB Activation and ERK Phosphorylation**

It has been reported that the transcription factor NF-κB is centrally involved in the induction of MMP-9 expression by PMA.

---

**Figure 4. Effect of AE-BCT on NF-κB activation in HT1080 cells.** (A) Control and AE-BCT-pre-treated HT1080 cells were stimulated with 5 nM PMA for the indicated periods of time and cell lysates were subjected to Western blotting of the phosphorylation and degradation of IκBa. (B) To examine the nuclear translocation of the NF-κB p65 subunit in response to PMA stimulation, cell lysates were fractionated into cytosolic and nuclear compartments, and subjected to Western blotting. After normalization to α-tubulin or TBP expression, relative ratios of pIκBa/IκBa and nuclear p65/cytosolic p65 were determined. Data are expressed as means ± SD of two independent experiments. **p<0.01 vs no AE-BCT.

doi:10.1371/journal.pone.0078061.g004
and enhancement of tumor invasion in various cells [12,22,23]. To investigate whether the inhibitory effect of AE-BCT on MMP-9 expression and invasion was linked to the suppression of NF-κB activity, we examined the levels of IκBα and phospho-IκBα, along with p65 nuclear translocation, by Western blotting. As shown in Fig. 4A, IκBα phosphorylation in control HT1080 cells was immediately increased by PMA stimulation, a response accompanied by IκBα degradation. The increase in IκBα phosphorylation and decrease in IκBα levels in response to PMA stimulation was markedly lower in AE-BCT-treated HT1080 cells than in control cells. In control cells, the p65 subunit rapidly translocated from the cytosol to the nucleus after PMA stimulation. In AE-BCT-treated cells.

Figure 5. Effect of AE-BCT on MAPK activation in HT1080 cells. Control and AE-BCT-pre-treated HT1080 cells were stimulated with 5 nM PMA for the indicated period of time and cell lysates were subjected to Western blotting of the phosphorylation of p38, ERK, and JNK. Relative ratios of phosphorylated forms to total levels were determined after normalization to α-tubulin expression. Data are expressed as means ± SD of two independent experiments. **p<0.01 vs no AE-BCT.
doi:10.1371/journal.pone.0078061.g005

Anti-Metastatic Effect of Bamboo Shavings

PLOS ONE | www.plosone.org 8 October 2013 | Volume 8 | Issue 10 | e78061
cells, p65 nuclear translocation was inhibited significantly (Fig. 4B). These observations collectively suggest that AE-BCT inhibits the migration and invasion of HT1080 cells by reducing MMP-9 activity via repression of NF-κB activation. In many studies, it has been demonstrated that the activation of mitogen-activated protein kinases (MAPKs) including ERK1/2, p38, and JNK1/2

**Figure 6. Effect of AE-BCT on intracellular ROS generation, and involvement of ROS in NF-κB activation and MMP-9 activity.** (A) Cells pre-treated with NAC (1 mM) for 1 h or AE-BCT (50 μg/ml) for 12 h were stimulated with PMA (5 nM) for 3 h, incubated with DCF-DA (5 μM) for 30 min at 37°C, and then subjected to flow cytometry assay of ROS levels. Data are expressed as means ± SD of three independent experiments. **p<0.01 vs untreated control, †p<0.01 vs PMA stimulation (B) Cells pre-treated with NAC or AE-BCT were stimulated with PMA (5 nM) for 60 min, and pIκBα and IκBα protein levels were determined by Western blotting. (C) Conditioned media collected after 24 h of PMA stimulation were analyzed for MMP-9 activity and expression. Values are expressed as fold increases in band intensity compared with untreated control cells. Data are expressed as means ± SD of two independent experiments. **p<0.01 vs untreated control, †p<0.01 vs PMA stimulation.

doi:10.1371/journal.pone.0078061.g006
MMP-9 by gelatin zymography. **Conditioned media were collected and analyzed for the activity of serum-free medium with 20 ng/mL TNF-α. Cells pre-treated with 20 ng/ml TNF-α for the 30, 60, and 180 min and cell lysates were examined for the phosphorylation and degradation of IκBα. After normalization to β-tubulin expression, relative ratios of pIκBα/IκBα were determined. Data are expressed as means ± SD of two independent experiments. **p<0.01 vs no AE-BCT. (E) Cells (3 x 10^5) 200 μL PBS) were injected into the tail veins of 6-week-old female C57BL/6J mice, to which AE-BCT (50 or 100 mg/kg) was administered daily. At day 17, mice were killed and the black colonies on the lung surface were enumerated macroscopically. Images of metastatic lung nodules at the front (F) and back (B) are shown. Colonies were enumerated and relative inhibition compared with the control group was calculated. Data are representative of two independent experiments (n = 5 per group). **p<0.01 vs saline control.

doi:10.1371/journal.pone.0078061.g007

is critical for the increase in MMP-9 activity and expression in response to various agonists, and that these MAPKs act as upstream modulators of NF-κB or AP-1 [23–25]. MAPK inhibitors markedly suppressed PMA-induced MMP-9 promoter activity, suggesting that MAPK signaling pathways are indispensable for the full activation of MMP-9. As shown in Fig. 5, in control cells, PMA rapidly induced the phosphorylation of p38, ERK1/2, and JNK1/2. AE-BCT significantly inhibited the PMA-induced phosphorylation of ERK1/2, but had little effect on p38 and JNK1/2 phosphorylation, suggesting that the specific inhibition of ERK activation is involved in the inhibition of PMA-induced MMP-9 activity by AE-BCT.

AE-BCT Suppresses PMA-induced ROS Production and Inhibits Subsequent NF-κB Activation and MMP-9 Activity

Previous experiments demonstrated that PMA triggers pro-MMP-2 activation through NF-κB activation via ROS production [26], and that ROS production contributes to the expression and activity of MMP-9 in various cell types [11,12]. To determine whether suppression of the PMA-induced increase in MMP-9 activity by AE-BCT is related to its ROS-scavenging activity, we determined the effect of AE-BCT on the PMA-induced ROS production in HT1080 cells by flow cytometry. As previously reported, we found that PMA markedly increased intracellular ROS levels (~6.5-fold), whereas the ROS scavenger NAC almost completely blocked ROS production [Fig. 6A] [12]. In addition, NAC fully inhibited PMA-induced IκBα phosphorylation and IκBα degradation, and reduced MMP-9 activity and expression (Fig. 6B–C), confirming that ROS production in HT1080 cells in response to PMA is related to NF-κB activation and increased MMP-9 activity. Interestingly, AE-BCT also reduced PMA-enhanced intracellular ROS production by ~70% compared to PMA-stimulated control cells, inhibited IκBα phosphorylation and IκBα degradation, and suppressed MMP-9 activity (Fig. 6A–C). These data suggest that AE-BCT inhibits the PMA-induced

| Treatment | Body Weight (g) |
|-----------|----------------|
|           | Day 0 | Day 5 | Day 10 | Day 15 |
| control   | 17.43±0.36 | 18.68±0.57 | 18.82±0.73 | 19.21±0.41 |
| 50 mg/kg  | 17.38±0.34 | 18.51±0.42 | 18.64±0.30 | 19.03±0.52 |
| 100 mg/kg | 17.43±0.35 | 18.65±0.45 | 18.99±0.12 | 19.34±0.17 |

Data are presented as mean ± SD. Each group of mice (n = 3) were orally administrated with 50 or 100 mg/kg daily and weighed body weight at 0, 5, 10, and 15 days.

doi:10.1371/journal.pone.0078061.t001
increase in metastatic activity by suppressing NF-κB activation through ROS signaling.

AE-BCT also Suppresses Metastatic Potential of Murine B16F10 Melanoma Cells

To demonstrate the anti-metastatic effect of AE-BCT in vivo, we utilized murine B16F10 melanoma cells, which are highly metastatic in syngenic C57BL/6J mice. First, we investigated the effect of AE-BCT at non-cytotoxic doses on the in vitro metastatic potential. As demonstrated in the HT1080 cell system, AE-BCT treatment in B16F10 cells almost completely prevented anchorage-independent colony formation (Fig. 7A) and the migratory and invasive capabilities (Fig. 7B) in a dose-dependent manner. In B16F10 cells, TNF-α was used as an inducer of MMP-9 activity and NF-κB activation [22]. As shown in Fig. 7C, TNF-α-induced MMP-9 secretion in B16F10 cells was also significantly decreased by AE-BCT. We then examined the effect of AE-BCT on TNF-α-induced NF-κB activation. As expected, stimulation with TNF-α in untreated control B16F10 cells increased the ratio of pIκBζ/IκBζ to about 5-fold, but AE-BCT treatment dramatically prevented the increase in the ratio of pIκBζ/IκBζ in response to TNF-α stimulation (Fig. 7D). These results indicate again that AE-BCT attenuates invasive potential via suppression of NF-κB activation.

AE-BCT Administration Remarkably Inhibits in vivo Pulmonary Metastasis of B16F10 Cells

We next examined the inhibitory effect of AE-BCT on the ability of B16F10 cells to colonize in the lungs of C57BL/6J mice after intravenous injection. As shown in Fig. 7E, black pulmonary metastatic colonies were significantly decreased by AE-BCT administration (<30% of the control group values at doses of 50 and 100 mg/kg). To investigate whether repeated administration of AE-BCT during the experimental period is systematically non-toxic, mice were treated with saline only (control) or AE-BCT at a dose of 50 or 100 mg/kg. The administration of AE-BCT for 15 days did not cause death or abnormal behavior, and did not affect weight gain (Table 1) or organ weights (Table 2). In serological analyses, the AST/ALT and BUN/CRE ratios were not significantly altered in the AE-BCT-treated group compared to the control group, suggesting that AE-BCT administration did not induce hepatic or renal damage (Table 3). In hematological analyses, numbers of RBCs and Hb levels, indicators of anemia, were not significantly changed by AE-BCT, and numbers of WBCs and other parameters in AE-BCT-treated mice were all within normal ranges (Table 4). These data show that AE-BCT administration effectively inhibited pulmonary metastasis of B16F10 cells compared to controls, without causing any side effects.

### Table 2. Organ weights of mice administrated with 50 mg/kg or 100 mg/kg of AE-BCT.

| Treatment | Weight of organs (g) |
|-----------|---------------------|
|           | Liver | Heart | Lung | spleen | Kidney (L) | Kidney (R) |
| Control   | 1.08±0.04 | 0.10±0.02 | 0.15±0.01 | 0.08±0.01 | 0.12±0.01 | 0.12±0.01 |
| 50 mg/kg  | 1.08±0.01 | 0.10±0.01 | 0.13±0.01 | 0.07±0.00 | 0.11±0.00 | 0.12±0.01 |
| 100 mg/kg | 0.94±0.08 | 0.11±0.01 | 0.15±0.01 | 0.08±0.01 | 0.12±0.01 | 0.12±0.02 |

Data are presented as mean ± SD. Each group of mice (n = 3) were orally administrated with 50 or 100 mg/kg daily, sacrificed at 15 days, and weighed organs. doi:10.1371/journal.pone.0078061.t002

### Table 4. Hematological analysis of bloods obtained from mice administrated with 50 mg/kg or 100 mg/kg of AE-BCT.

| Parameter | control | 50 mg/kg | 100 mg/kg |
|-----------|---------|----------|-----------|
| WBCP (<10^6 cells/µL) | 1.8±0.58 | 1.9±0.27 | 1.9±0.13 |
| WBCB (<10^6 cells/µL) | 1.9±0.56 | 1.8±0.21 | 1.9±0.10 |
| RBC (<10^6 cells/µL) | 9.5±0.30 | 10.4±0.61 | 9.4±0.01 |
| Means HGB (g/dL) | 13.6±0.30 | 13.9±0.06 | 13.7±0.00 |
| HCT (%) | 54.5±1.01 | 53.3±1.11 | 53.8±0.64 |
| MCV (fL) | 57.5±1.10 | 59.6±0.54 | 57.5±0.63 |
| MCH (pg) | 14.4±0.26 | 14.3±0.03 | 14.6±0.01 |
| MCHC (g/dL) | 24.9±0.57 | 24.0±0.51 | 25.5±0.28 |
| PLT (<10^6 cells/µL) | 97.1±17.5 | 95.8±11.4 | 89.3±1.84 |
| % NEUT | 9.7±1.96 | 9.20±0.07 | 9.9±0.37 |
| % LYM | 86.5±1.85 | 90.5±0.25 | 85.7±2.62 |
| % MONO | 0.5±0.11 | 0.5±0.09 | 0.5±0.10 |

Data are presented as mean ± SD. Each group of mice (n = 3) were orally administrated with 50 or 100 mg/kg daily, sacrificed at 15 days, and analyzed hematologic parameters.

| Parameter | control | 50 mg/kg | 100 mg/kg |
|-----------|---------|----------|-----------|
| AST (IU/L) | 52.7±3.1 | 29.3±4.6 | 186.7±25.4 |
| ALT (IU/L) | 56.0±6.3 | 28.0±1.4 | 156.2±11.3 |
| ALP (IU/L) | 59.0±2.0 | 30.2±2.0 | 161.0±10.2 |
| BUN (mg/dL) | 36.5±1.5 | 36.8±3.6 | 39.0±5.2 |
| CRE (mg/dL) | 0.7±0.1 | 0.4±0.1 | 0.8±0.3 |

Data are presented as mean ± SD. Each group of mice (n = 3) were orally administrated with 50 or 100 mg/kg daily, sacrificed at 15 days, and analyzed hematologic parameters.

| Parameter | control | 50 mg/kg | 100 mg/kg |
|-----------|---------|----------|-----------|
| WBCP (<10^6 cells/µL) | 1.8±0.58 | 1.9±0.27 | 1.9±0.13 |
| WBCB (<10^6 cells/µL) | 1.9±0.56 | 1.8±0.21 | 1.9±0.10 |
| RBC (<10^6 cells/µL) | 9.5±0.30 | 10.4±0.61 | 9.4±0.01 |
| Means HGB (g/dL) | 13.6±0.30 | 13.9±0.06 | 13.7±0.00 |
| HCT (%) | 54.5±1.01 | 53.3±1.11 | 53.8±0.64 |
| MCV (fL) | 57.5±1.10 | 59.6±0.54 | 57.5±0.63 |
| MCH (pg) | 14.4±0.26 | 14.3±0.03 | 14.6±0.01 |
| MCHC (g/dL) | 24.9±0.57 | 24.0±0.51 | 25.5±0.28 |
| PLT (<10^6 cells/µL) | 97.1±17.5 | 95.8±11.4 | 89.3±1.84 |
| % NEUT | 9.7±1.96 | 9.20±0.07 | 9.9±0.37 |
| % LYM | 86.5±1.85 | 90.5±0.25 | 85.7±2.62 |
| % MONO | 0.5±0.11 | 0.5±0.09 | 0.5±0.10 |

Data are presented as mean ± SD. Each group of mice (n = 3) were orally administrated with 50 or 100 mg/kg daily, sacrificed at 15 days, and analyzed hematologic parameters.

| Parameter | control | 50 mg/kg | 100 mg/kg |
|-----------|---------|----------|-----------|
| AST (IU/L) | 52.7±3.1 | 29.3±4.6 | 186.7±25.4 |
| ALT (IU/L) | 56.0±6.3 | 28.0±1.4 | 156.2±11.3 |
| ALP (IU/L) | 59.0±2.0 | 30.2±2.0 | 161.0±10.2 |
| BUN (mg/dL) | 36.5±1.5 | 36.8±3.6 | 39.0±5.2 |
| CRE (mg/dL) | 0.7±0.1 | 0.4±0.1 | 0.8±0.3 |

Data are presented as mean ± SD. Each group of mice (n = 3) were orally administrated with 50 or 100 mg/kg daily, sacrificed at 15 days, and analyzed hematologic parameters.

C BC, complete blood cell count; WBCP, white blood cell count peroxidase method; WBCB, white blood cell count basophile method; RBC, red blood cell count; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; PLT, platelet; NEUT, neutrophil; LYM, lymphocyte; MONO, monocyte. doi:10.1371/journal.pone.0078061.t0003
MMP-9 activity via suppression of ROS-mediated NF-kB activation of malignant HT1080 cells by reducing aqueous extract of Bamfusae Caulis in Taeniam, reduces the effects due to the non-selective killing of proliferating cells, AE-growth and/or induce apoptosis are linked to severe adverse period (Tables 1–4). Since many anti-cancer drugs that inhibit cell cause any sub-acute systemic toxicity during the experimental colonies, and intake of effective doses of 50 and 100 mg/kg did not dependent reduction in the number of pulmonary metastatic administration of effective doses of AE-BCT significantly de-

In the present study, we demonstrated that AE-BCT, the aqueous extract of Bamfusae Caulis in Taeniam, reduces the metastatic potential of malignant HT1080 cells by reducing MMP-9 activity via suppression of ROS-mediated NF-kB activation under conditions of PMA stimulation, and prevents pulmonary metastasis of B16F10 melanoma cells in vivo (Fig. 1–7). Notably, long-term daily administration of AE-BCT led to a dose-dependent reduction in the number of pulmonary metastatic colonies, and intake of effective doses of 50 and 100 mg/kg did not cause any sub-acute systemic toxicity during the experimental period (Tables 1–4). Since many anti-cancer drugs that inhibit cell growth and/or induce apoptosis are linked to severe adverse effects due to the non-selective killing of proliferating cells, AE-BCT, which inhibits tumor growth and metastasis with little or no toxicity, can potentially be used to improve the efficiency of cancer treatment and to enhance the survival of cancer patients.

Tumors with invasive and metastatic potential are known to be relatively resistant to current chemotherapeutic agents and are consequently related to poor prognoses and high mortality rates in cancer patients. Metastasis occurs after degradation of the basement membrane and stromal ECM via activation of type IV collagen-degrading enzymes, mainly MMP-2 and MMP-9. In recent studies, it was reported that MMP-9 expression is intimately linked to vascular invasion and aggressiveness and that MMP-2 is closely associated with adverse prognosis and relapse in breast cancer [4,18,19]. Thus, agents and/or natural plant products that inhibit both the expression and activity of these MMPs have received considerable attention for their potential use in the treatment of malignant invasive cancer cells.

MMP-9 is regulated by activation of MAPKs in response to various agonists, including cytokines, growth factors, and PMA. In previous studies, PMA-induced MMP activation was significantly decreased by ERK1/2, p38, and JNK inhibitors [26,27]. In this study, PMA induced MAPK activation, and AE-BCT exhibited inhibitory effects on the phosphorylation of ERK, but not p38 or JNK, after PMA stimulation (Fig. 5). MAPK activation leads to the sequential activation of the transcription factors AP-1 and NF-kB, which are involved in many pathological processes, such as cancer cell adhesion, invasion, metastasis, and angiogenesis. In accordance with earlier reports that MMP-9 activation in PMA-stimulated HT1080 cells is mediated by the activation of NF-kB [29], AE-BCT inhibited the phosphorylation and degradation of IkBz, and nuclear translocation of p65, and concurrently reduced PMA-induced MMP-9 activity (Fig. 4). It has been demonstrated that ROS play a critical role in the activation of NF-kB. The antioxidant pyrrolidine dithiocarbamate blocked the nuclear translocation of NF-kB [29], and the DNA-binding activity of NF-kB was inhibited by antioxidants such as quercetin and vitamin E [30,31]. In addition, ROS scavengers, such as r-hSOD and NAC inhibited invasive and metastatic activities of malignant cells via suppression of MMP-9 activity [12,32]. In the present study, we found that AE-BCT decreased intracellular ROS levels in PMA-stimulated HT1080 cells (Fig. 6A), and that its ROS-scavenging activity was correlated with NF-kB activation and MMP-9 activity (Fig. 6B–C).

In conclusion, our results demonstrate that AE-BCT exerts anti-metastatic effects on highly malignant cancer cells by suppressing MMP-9 activity through inhibition of ROS-mediated NF-kB activation (Fig. 8). Moreover, we found that repeated oral administration of effective doses of AE-BCT significantly decreased the number of pulmonary metastatic colonies in mice injected intravenously with B16F10 melanoma cells, with no systemic toxicity. Collectively, these results suggest that AE-BCT may be a safe natural product for controlling metastatic cancer.

The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/VS24n.

Author Contributions
Conceived and designed the experiments: AYK JYM. Performed the experiments: AYK MJH NHY YPJ. Analyzed the data: AYK, JYM. Contributed reagents/materials/analysis tools: AYK JYM. Wrote the paper: AYK.

1. Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327–336.

2. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563–572.
3. Patel LR, Camacho DF, Shiosawa Y, Pienta KJ, Taichman RS (2011) Mechanisms of cancer cell metastasis to the bone: a multi-step process. Future Oncol 7: 1285–1297.

4. Janga DC, Bhardwaj A, Coudrea I, Ardeleanu C, Dragonin C et al (2006) MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med 10: 499–510.

5. Kim TS, Kim YB (1999) Correlation between expression of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) and angiogenesis in colorectal adenocarcinoma. J Korean Med Sci 14: 267–270.

6. McCavey IJ, Matrisian LM (2000) Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 6: 149–156.

7. Gondh CS, Lakka SS, Dush DH, Offero WC, Gurgati M et al (2004) Downregulation of uPA, uPAR and MMP-9 using small interfering hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol 1: 165–176.

8. Jiang ZQ, Zhu FC, Qu JY, Zheng X, You CL (2003) Relationship between expression of matrix metalloproteinase (MMP-9) and tumor angiogenesis, cancer cell proliferation, invasion, and metastasis in invasive carcinoma of cervix. Chin. J Cancer 22: 178–184.

9. Leung CA, Selkon HS, Arora V, Stein DA, Iversen PL et al (2003) A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 10: 823–832.

10. Hsieh HL, Wang HH, Wu WB, Chu PJ, Yang CM (2010) Transforming growth factor-β1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK-NF-κB pathways. J Neuroinflammation 7: 88.

11. Tobar N, Villar V, Santibanez JP (2010) ROS-NF-κB mediates TGF-β1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol Cell Biochem 340: 195–202.

12. Lee KJ, Hwang SJ, Choi HJ, Jeong HG (2008) Saponins derived from the roots of Platycodon grandiflorum inhibit HT-1080 cell invasion and MMPs activities: regulation of NF-κB activation via ROS signal pathway. Cancer Lett 268: 233–243.

13. Jiao J, Zhang Y, Lou D, Wu X (2007) Anti-hyperlipidemic and antihypertensive roles of ROS-dependent ERK- and JNK-NF-κB pathways. Mol Med Today 6: 149–156.

14. Jung SH, Lee JM, Lee HJ, Kim CY, Lee EH et al (2007) Adverse reductase and advanced glycation endproducts inhibitory effect of Phyllostachys nigra. Biol Pharm Bull 30: 1560–1572.

15. Ra J, Lee S, Kim HJ, Jang YP, Ahn H et al (2010) Bambusa Caullia in Taeinian extract reduces ovulation-induced airway inflammation and T helper 2 responses in mice. J Ethnopharmacol 128: 241–247.

16. Jin GH, Park SY, Kim E, Ryu EY, Kim YH et al (2012) Anti-inflammatory activity of Bambusa Caullia in Taeinian through heme oxygenase-1 expression via Nrf2 and p38 MAPK signaling in macrophages. Environ Toxicol Pharmacol 34: 315–323.

17. Eom HW, Park SY, Kim YH, Seong SJ, Jin ML et al (2012) Bambusa Caullia in Taeinian modulates neuroprotective and anti-neuroinflammatory effects in hippocampal and microglial cells via HO-1 and Nrf-2-mediated pathways. Int J Mol Med 30: 1512–1520.

18. Han I, Yang G, Lee J, Lee KJ, Choi HY (2009) Hypodiploidic effect of Morchella officinarum in Taeinian in hyperlipidemia induced by Triton WR-1339 and high cholesterol diet in rats. Immunopharmacol Immunotoxicol 31: 439–445.

19. Lu B, Liu L, Chen X, Wu X, Zhang Y (2010) Anti-tumor activity of triterpenoid-rich extract from bamboo shavings (Caullia bambusae in Taeinian). Afr J Biotechnol 9: 6430–6436.

20. Lee KJ, Kim YJ, Choi JH, Kim HG, Chung YC et al (2006) Inhibition of tumor invasion and metastasis by aqueous extract of the radix of Platycodon grandiflorum. Food Chem Toxicol 44: 1890–1896.

21. Bussemakers MJ, Schalken JA (1996) The role of cell adhesion molecules and proteases in tumor invasion and metastasis. World J Urol 14: 151–156.

22. Kim A, Kim MJ, Yang Y, Kim JW, Yeom YI et al (2009) Suppression of NF-κB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells Carcinogenesis 30: 927–936.

23. Choi JH, Han EH, Hwang YP, Choi JM, Choi CY et al (2010) Suppression of PMA-induced tumor cell invasion and metastasis by aqueous extract isolated from Prunella vulgaris via the inhibition of NF-κB-dependent MMP-9 expression. Food Chem Toxicol 48: 564–571.

24. Yang SF, Chen MK, Hsieh YS, Yang JS, Zavras AI et al (2010) Antimetastatic effects of Terminalia catappa L. on oral cancer via a down-regulation of metastasis-associated proteases. Food Chem Toxicol 48: 1052–1058.

25. Lee SO, Jeong YJ, Yu MH, Lee JW, Hwsangbo MH et al (2006) Wogonin suppresses TNF-α-induced MMP-9 expression by blocking the NF-κB activation via MAPK signaling pathways in human aortic smooth muscle cells. Biochem Biophys Res Commun 351: 118–123.

26. Binkert MG, Binkert-Cosen AA, Gaisano HY, de Cosen RH, Cosen-Binker LJ (2011) TGF-beta1 increases invasiveness of SW1900 cells through Rac1/ROS/NF-κB/IL-6/MMP-2. Biochem Biophys Res Commun 405: 140–145.

27. Seki T, Kida K, Maeda H (2010) Immunostimulation-Mediated Anti-tumor Activity of Bamboo (Sasa senanensis) Leaf Extracts Obtained Under 'Vigorous' Condition. Evid Based Complement Alternat Med 7: 447–457.

28. Tsuoda S, Yamamoto K, Sakamoto S, Inoue H, Nagasawa H (1998) Effects of Sasa Health, extract of bamboo grass leaves, on spontaneous mammary tumourigenesis in SHN mice. Anticancer Res 18: 153–158.

29. Morain C, Gole G, Johnson DW, Healy H (2010) Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma. Apoptosis 15: 412–423.

30. Kim BH, Choi JS, Yi EH, Lee JK, Won C et al (2013) Relative antioxidative activities of quercetin and its structurally related substances and their effects on NF-κB/CRE/AP-1 signaling in marine macrophages. Mol Cells 35: 410–20.

31. Yi L, Chen CY, Jin X, Zhang T, Zhou Y et al (2012) Differential suppression of intracellular reactive oxygen species-mediated signaling pathway in vascular endothelial cells by several subclasses of flavonoids. Biochimie 94: 2035–2044.

32. Kim SC, Maghey V, Jeong SJ, Lee HJ, Ahn KS et al (2010)Ethanol extract of Ocimum sanctum exerts antimetastatic activity through inactivation of matrix metalloproteinase-9 and enhancement of anti-oxidant enzymes. Food Chem Toxicol 48: 1478–1482.